[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
January 2010

The Safety and Efficacy of Pimecrolimus, 1%, Cream for the Treatment of Netherton SyndromeResults From an Exploratory Study

Author Affiliations

Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(1):57-62. doi:10.1001/archdermatol.2009.326

Background  Impaired skin integrity in patients with Netherton syndrome (NS) results in significant systemic absorption of topically applied medications. Some have advocated the administration of pimecrolimus, 1%, topical cream for the treatment of patients with NS. Insufficient data exist with regard to its safety, systemic absorption, and efficacy.

Observations  An exploratory study was conducted involving 3 children with NS who received twice-daily application of pimecrolimus, 1%, cream over 18 months. There were no notable abnormalities in hematologic or chemistry profiles. Blood levels of pimecrolimus ranged from 0.625 to 7.08 ng/mL, with peak levels reached during the first month in all 3 patients. Dramatic reductions were observed in the Netherton Area and Severity Assessment, Eczema Area and Severity Index, Investigator Global Evaluation of Disease, and pruritus scores compared with baseline levels.

Conclusions  Use of pimecrolimus, 1%, cream was well tolerated and demonstrated marked improvements in nearly all of the parameters evaluated. Patients treated with pimecrolimus responded rapidly, within the first month of treatment, and improvement persisted throughout the study period. In adult patients receiving oral pimecrolimus, blood levels as high as 54 ng/mL for 3 months have not shown clinically significant immunosuppression. Absorption of pimecrolimus, 1%, cream was detectable, but levels were much lower than expected even when applied to 50% of total body surface area. Larger studies are warranted to determine the safety and efficacy of pimecrolimus, 1%, cream in the treatment of NS.

Trial Registration  clinicaltrials.gov Identifier: NCT00208026

Netherton syndrome (NS) (OMIM 256500)1 is an autosomal recessive genodermatosis and is classified as a congenital ichthyosis. Affected patients typically manifest with neonatal erythroderma; a chronic eczematous dermatitis; ichthyosis linearis circumflexa (ILC); and sparse, brittle hair with characteristic findings of trichorrhexis invaginata. Other findings include a predisposition to food allergies; elevated IgE levels and other immunologic abnormalities; and failure to thrive in association with intestinal malabsorption. Netherton syndrome is attributed to mutations in the gene encoding the serine protease inhibitor Kazal-type 5 (SPINK5).2

The cutaneous manifestions of NS are not infrequently resistant to conventional therapy (emollients and topical corticosteroids). Topical calcineurin inhibitors—tacrolimus and pimecrolimus—have been demonstrated to improve the skin findings and quality of life of patients with several chronic dermatoses, including atopic dermatitis. Owing to the underlying skin barrier dysfunction, the possibility of significant systemic absorption and resultant adverse effects remains a real concern when these agents are used in patients with NS.

It therefore seems only prudent to more fully investigate the absorption, safety, and efficacy of pimecrolimus for use in patients with NS given the documented history of clinically significant systemic absorption with other comparable topical agents before its routine use can be recommended. This study evaluates the safety and efficacy of pimecrolimus cream in patients with NS and includes pharmacokinetic measurements of blood pimecrolimus levels.

Experimental protocol

This was an open-label, single-arm study to investigate the safety profile of topical pimecrolimus cream, 1% (Elidel; Novartis Pharmaceuticals Corp, East Hanover, New Jersey), in the treatment of the cutaneous manifestations associated with NS. The study was approved by the institutional review board of the Children's Hospital of Philadelphia.3

Enrolled patients were treated with conventional dosing of commercially available pimecrolimus, 1%, cream used twice daily as needed applied to affected areas. Patients were asked to limit application to no more than 50% of their total body surface area. The percentage of body surface area affected, and the total dose of pimecrolimus applied, as measured in grams, were determined for all patients at each follow-up visit. Patients 1 and 2 treated their ILC, whereas patient 3 treated the erythrodermic skin changes associated with her NS.

At each visit, routine blood tests to assess electrolytes, fasting glucose, liver, renal, and hematopoietic functions was performed at the Children's Hospital of Philadelphia. Blood samples for pharmacokinetic measurements of pimecrolimus were drawn 1.5 hours after medication was applied on the study day. These samples were then shipped frozen via overnight courier to the Novartis bioanalytics reference laboratory located in Rueil-Malmaison, France, and there were subjected to a liquid chromatography/tandem mass spectrometry assay. The occurrence of adverse effects was evaluated by the use of standard questionnaires.

Measures of clinical improvement of the dermatitis were assessed using both physician-determined scoring systems and patient-based self-assessments. Physician-determined scores included the Eczema Area and Severity Index (EASI), the Netherton Area and Severity Assessment (NASA) (eTable), a standard Investigator's Global Evaluation of Disease (IGED), and transepidermal water loss (TEWL) measurements using the noninvasive Vapometer device (Delfin Technologies, Kuopio, Finland). Patient-based self-assessments included pruritus scores and the Children's Dermatology Quality of Life Index (CDQLI) used with the permission of M. Susan Lewis-Jones, FRCP, FRCPCH (Ninewells Hospital and Medical School, Dundee, Scotland), and Andrew Y. Finlay, MBBS, FRCP (Cardiff University School of Medicine, Cardiff, Wales).4,5

Phase 1 of the study consisted of a series of visits over a 3-month period: an initial screening visit, followed by visits on days 1, 8, 14, 28, 56, and 84.

Phase 2 of the study consisted of a 15-month extension period. Patients and their families who chose to continue therapy after the initial phase were offered the opportunity to continue on in phase 2, during which additional evaluations (identical to evaluation visits during phase 1) and monitoring were performed at the additional time points of 6 months, 12 months, and 18 months (as determined from the time of enrollment in the original study).

Study participants

Patients meeting the criteria for diagnosis of NS were enrolled over a period of 3 years, from September 2005 through March 2008. During this time, 1 set of twin girls 12 years of age, and 1 girl 7 years of age entered the study.

Enrolled patients all had normal laboratory values within 3 months prior to enrollment and provided signed written informed consent and assent. Patients of child-bearing age underwent pregnancy testing during the trial. Washout periods were required for those using systemic steroids (4 weeks), systemic tacrolimus (4 weeks), immunosuppressive therapy (4 weeks), phototherapy (4 weeks), inhibitors of Cytochrome P 3A4 450 (CYP3A4) isoenzyme (2 weeks), topical tacrolimus (2 weeks), or topical pimecrolimus (2 weeks). Other prior topical therapies were discontinued the day before the therapy with pimecrolimus was begun. Any patient with a history of immune compromise, malignant disease, lymphoproliferative disorder, hypersensitivity or adverse reactions to macrolides or calcineurin inhibitors, or active viral, fungal, or untreated bacterial infection were excluded from participation in the study.


All 3 patients completed phase 1. The families of all 3 patients elected to continue into phase 2.


During the 18-month trial, use of pimecrolimus was documented on the basis of the weight of tubes used. Patient 1 used 2045 g, patient 2 used 1167 g, and patient 3 used 5426 g, yielding a mean daily usage of 3.9 g/d, 2.2 g/d, and 9.7 g/d, respectively.


During the 18-month observation period, a mild eosinophilia was noted at baseline and intermittently throughout the study in all 3 patients. A mild transaminitis arose in patient 1 in conjunction with a viral illness. Otherwise, no clinically significant abnormalities were observed in complete blood cell counts, hepatic function testing, electrolytes, blood urea nitrogen, or glucose monitoring. Peak levels of blood pimecrolimus ranged from 0.625 to 7.08 ng/mL (Table) with maximal levels reached during the first month of treatment in all 3 patients (Figure 1). Patients 1 and 2 had predominantly cutaneous findings of ILC without erythroderma and demonstrated lower blood pimecrolimus levels. The higher blood levels in patient 3 were seen in association with erythrodermic skin findings.

Figure 1
Peak blood pimecrolimus levels in study patients over the 18-month treatment period.

Peak blood pimecrolimus levels in study patients over the 18-month treatment period.

Blood Pimecrolimus Levels in 3 Patients
Blood Pimecrolimus Levels in 3 Patients

Baseline scores for EASI and NASA (a Netherton-specific modification of the EASI score that substitutes scaling for excoriation; see the eAppendix for details) were determined and compared with values obtained during treatment. Peak reductions from NASA baselines ranged from 54.1% to 91.7% and were reached 350 to 520 days into the study (Figure 2). Comparable findings were observed in EASI scores with maximal reductions of 62.5% to 92.4% from baseline, reached 84 to 561 days after the start of the study (Figure 3). Notable and rapid improvement in scores were seen with both NASA and EASI as early as 1 week into therapy (Figure 2 and Figure 3).

Figure 2
Netherton Area and Severity Assessment (NASA).

Netherton Area and Severity Assessment (NASA).

Figure 3
Eczema Area and Severity Index (EASI).

Eczema Area and Severity Index (EASI).

Similar improvements in Investigator Global Evaluation of Disease, which was graded on a 5-point, 0 to 4 scale (see the eAppendix). A peak reduction of IGED scores of 55% to 75% was evident after 28 to 84 days.

Scores for the CDQLI (Figure 4) were likewise observed, with patients describing improvements transitioning from moderate disease states to feeling essentially normal (total CDQLI scores of 0 and 1) and were manifest by 2 months into therapy with some maintaining notably improved quality-of-life measures well to the end of the study period (Figure 4). All 3 patients experienced complete subjective resolution of their pruritus at some point during the treatment period. In fact, most of the improvement occurred within 1 week of starting therapy.

Figure 4
Children's Dermatology Quality of Life Index (CDQLI) (developed by Lewis-Jones and Finlay). For patient 3, scores were provided by her mother.

Children's Dermatology Quality of Life Index (CDQLI) (developed by Lewis-Jones and Finlay4). For patient 3, scores were provided by her mother.

Although all 3 patients showed marked improvement in NASA, EASI, IGED, and CDQLI scores, statistically significant differences between baseline measurements and final measurements at the level of P = .05 is not possible with such a small number of patients. Nevertheless, all of these measures showed striking improvement in all of the patients (Figure 5 and Figure 6).

Figure 5
Clinical images of patient 1 before and after initiating therapy. A, Right flank on day 1; B, right flank on day 28.

Clinical images of patient 1 before and after initiating therapy. A, Right flank on day 1; B, right flank on day 28.

Figure 6
Clinical images of patient 2 before and after initiating therapy. A, Anterior lower legs on day 1; B, anterior lower legs on day 28.

Clinical images of patient 2 before and after initiating therapy. A, Anterior lower legs on day 1; B, anterior lower legs on day 28.

Interestingly, no consistent trends were noted in measurements of transepidermal water loss among patients in this study. The 2 older patients with predominantly ILC saw increases in TEWL as they clinically improved, but the device began malfunctioning at the 6-month visit and, unbeknownst to us at the time, required calibration. As a result, values obtained from that point on for patients 1 and 2 as well as all values for patient 3 were not counted. It was interesting to note that although the values for the younger patient (patient 3) could not be considered entirely valid, a trend was observed in which the more erythrodermic findings were associated with decreases in TEWL in association with improvements in clinical findings.


In patients with NS, the lack of appropriate protease inhibition within the epidermis results in impaired barrier function that can lead to increased TEWL, a predisposition to skin infection, as well as a marked permeability to topically applied agents. Hydrocortisone acetate, 1%, topical ointment, a low-potency topical corticosteroid, used over large body surface areas over a period of 1 year in an 11-year-old boy with NS resulted in Cushing syndrome.6 Experience with topical tacrolimus, 0.1%, ointment for patients with NS, for example, has shown both remarkable efficacy as well as striking systemic absorption of the drug in this patient population.7 Even when diluted to concentrations of 0.005%, 0.0075%, and 0.01% and used over limited body surface areas, topical tacrolimus ointment applied to the skin in patients with NS has demonstrated low but detectable systemic absorption.8

Pimecrolimus is an anti-inflammatory ascomycin macrolactam derivative that has demonstrated efficacy in the treatment of inflammatory skin disorders such as atopic dermatitis and contact dermatitis. The experience of using topical pimecrolimus, 1%, cream in patients with NS has been documented in case reports that have described 7 patients with evidence of both clinical efficacy and good clinical tolerability.911 In contrast to tacrolimus, measurement of pimecrolimus blood levels is not commercially available and currently can only be obtained through its manufacturer, Novartis.

There is a lack of sufficiently safe and effective options for treating the cutaneous manifestations of disease in children with NS. Use of pimecrolimus, 1%, cream was well tolerated and demonstrated clinically and statistically significant improvements in nearly all of the physician-rated and subject-rated parameters evaluated, including EASI, NASA, IGED, pruritus scores, and CDQLI. Patients treated with pimecrolimus responded rapidly, with subjective improvements occurring sooner than those rated by clinical observers. Itching responded most dramatically to treatment, within 1 week of starting therapy, whereas the improvements in cutaneous manifestations took slightly longer to manifest. Reductions in disease severity were clinically significant within the first month, and these improvements in clinical parameters persisted throughout the 18-month period of the study. Clinically significant tachyphylaxis was not observed during the study period.

The original study had been designed to evaluate patients over a 3-month period. However, owing to the notable clinical improvements observed, the patients and their families requested that they continue treatment with pimecrolimus. In an effort to provide ongoing monitoring for these families, an amendment to the original study was submitted to the institutional review board at the Children's Hospital of Philadelphia, and the protocol was approved for a 15-month extension for families wishing to extend their trial.

The use of topical tacrolimus has been associated with significant systemic absorption in children with NS.6,7 The absorption of pimecrolimus through the skin in patients with NS is, by contrast, considerably diminished, as demonstrated by the relatively low blood levels observed in these 3 patients. It seems that these observations would further validate previous studies that have suggested that the percutaneous absorption of pimecrolimus is significantly less than that seen with tacrolimus and corticosteroid preparations in the context of inflamed skin.12,13

In adult patients with psoriasis and atopic dermatitis receiving oral pimecrolimus, blood levels as high as 54 ng/mL for 3 months have not demonstrated apparent immunosuppression.14,15 In patients with NS, absorption of pimecrolimus, 1%, cream was detectable, but levels were much lower than expected even when applied to 50% of total body surface area for up to 18 months. No clinical evidence of immune suppression—increased rate of infections, opportunistic infections, hematologic abnormalities (eg, leukopenia, lymphopenia, or neutropenia)—were noted.

The biological meaning of detectable pimecrolimus blood levels remains unknown. Earlier animal studies indicated that exposures to high doses of calcineurin inhibitors such as tacrolimus and pimecrolimus were associated in a dose-dependent manner with the development of malignant skin diseases and lymphoma. Based in part on these data, the US Food and Drug Administration instituted a series of public health advisories, medication guides, and boxed warnings for both drugs to increase consumer awareness about this potential risk.1618 At the same time, more recent studies suggest alternative conclusions. A case-control study involving 5000 adults with dermatitis administered by questionnaire was designed to detect a 2-fold increased risk for nonmelanoma skin cancer in patients using topical calcineurin inhibitors. However, the analysis indicated instead that there was a dose-dependent decrease in the odds ratio for nonmelanoma skin cancer (range, 0.41-0.69) associated with the use of these agents when adjustments were made for age, sex, previous nonmelanoma skin cancer, and history of atopic dermatitis.19 Another study investigated the possible association of topical immunosuppressants and lymphoma in a cohort of patients with atopic dermatitis using a nested case-control design and identified 294 cases of lymphoma among 293 253 patients in the PharMetrics database. Adjusted analyses indicated that the use of topical calcineurin inhibitors was not independently associated with lymphoma, whereas the severity of atopic dermatitis seemed to be the most statistically significant factor associated with an increased risk of lymphoma.20

A correlation might exist between elevated blood pimecrolimus levels and the degree of calcineurin inhibition in circulating lymphocytes, which would then function as a highly sensitive marker for immune suppression. An assay for lymphocyte calcineurin inhibition, however, has only recently become available through the Novartis bioanalytics reference laboratory (during the final 6 months of this study) and could therefore not be successfully incorporated into the study prior to study end. Future investigations establishing baseline controls for lymphocyte calcineurin inhibition and measurements in patients with NS might help answer the question of whether these levels of blood pimecrolimus translate into measurable immunosuppression at the level of the lymphocyte and provide a basis for investigating whether these findings might have clinical relevance.

Pimecrolimus, 1%, cream applied topically seems to moderate the skin findings of patients with ILC and erythroderma seen in patients with NS. Although it is difficult to generalize from a small number of patients, it seems that the use of pimecrolimus cream is associated with very low levels of systemic absorption (less with ILC, and more absorption with erythrodermic NS, although these findings might be in part confounded by the fact that patients with ILC typically used less daily medication on average than the patient treating her erythrodermic skin changes). Given the favorable safety and efficacy profile encountered in this exploratory pilot study, and because patients with NS who respond to therapy are likely to desire continuing pimecrolimus as ongoing chronic treatment, larger studies and greater clinical experience are warranted to determine the longer-term safety and efficacy of pimecrolimus, 1%, cream in the treatment of NS.

Correspondence: Albert C. Yan, MD, Section of Dermatology, Children's Hospital of Philadelphia, 3550 Market St, Second Floor, Philadelphia, PA 19104 (yana@email.chop.edu).

Accepted for Publication: April 27, 2009.

Author Contributions: Dr Yan was the principal investigator for this study. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Yan, Honig, and Shah. Acquisition of data: Yan, Honig, Weber, and Shah. Analysis and interpretation of data: Yan, Honig, Ming, and Shah. Drafting of the manuscript: Yan. Critical revision of the manuscript for important intellectual content: Yan, Honig, Ming, Weber, and Shah. Statistical analysis: Yan and Ming. Obtained funding: Yan. Administrative, technical, and material support: Yan, Honig, Weber, and Shah. Study supervision: Yan, Honig, and Shah.

Financial Disclosure: Dr Yan has served as a consultant to Novartis.

Funding/Support: This study was investigator-initiated but supported in part by a research grant from Novartis.

Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Previous Presentations: Interim results from this study were presented in poster form at the Society for Pediatric Dermatology Annual Meeting; July 6-9, 2006; Montreal, Quebec, Canada; and at the American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.

Additional Contributions: We are indebted to our past clinical research coordinators, Christina Kubrak, RRT, NPS, and Donnette Paris, BS, RTR; our clinical research team members (Marsha Wallace, RN, CCRC, Donna Sylvester, RN, Sheri McDougall, MSHed, CCRC, Hien Nhan, Sonji Robinson, Anne Parneix-Spake, MD, Calogera McCormick, BA, Danièle Leroy, Marie-Noëlle Bizot, Barbara Taylor, RPh, Maria Figliomeni, Melly Kundla, and Richard Petruschke, PharmD.

 Netherton syndrome. Online Mendelian Inheritance in Man Web site.http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=256500Accessed September 27 2008
Chavanas  SBodemer  CRochat  A  et al.  Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome.  Nat Genet 2000;25 (2) 141- 142PubMedGoogle ScholarCrossref
 Safety study of Elidel (pimecrolimus) 1% cream to treat Netherton syndrome. http://www.clinicaltrials.gov/ct2/show/NCT00208026?term=Albert+Yan&rank=1Accessed October 19 2008
Lewis-Jones  MSFinlay  AY The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use.  Br J Dermatol 1995;132 (6) 942- 949PubMedGoogle ScholarCrossref
Holme  SAMan  ISharpe  SLDykes  PSLewis-Jones  MSFinlay  AY The Children's Dermatology Life Quality Index: validation of the cartoon version.  Br J Dermatol 2003;148 (2) 285- 290PubMedGoogle ScholarCrossref
Halverstam  CPVachharajani  AMallory  SB Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome.  Pediatr Dermatol 2007;24 (1) 42- 45PubMedGoogle ScholarCrossref
Allen  ASiegfried  ESilverman  R  et al.  Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome.  Arch Dermatol 2001;137 (6) 747- 750PubMedGoogle Scholar
Shah  KNYan  AC Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with Netherton syndrome.  Arch Dermatol 2006;142 (10) 1362- 1363PubMedGoogle ScholarCrossref
Saif  GBAl-Khenaizan  S Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings.  Int J Dermatol 2007;46 (3) 290- 294PubMedGoogle ScholarCrossref
Henno  AChoffray  ADe La Brassinne  M Improvement of Netherton syndrome associated erythroderma in two adult sisters through use of topical tacrolimus [in French].  Ann Dermatol Venereol 2006;133 (1) 71- 72PubMedGoogle ScholarCrossref
Oji  VBeljan  GBeier  KTraupe  HLuger  TA Topical pimecrolimus: a novel therapeutic option for Netherton syndrome.  Br J Dermatol 2005;153 (5) 1067- 1068PubMedGoogle ScholarCrossref
Meingassner  JGAschauer  HStuetz  ABillich  A Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.  Exp Dermatol 2005;14 (10) 752- 757PubMedGoogle ScholarCrossref
Billich  AAschauer  HAszodi  AStuetz  A Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.  Int J Pharm 2004;269 (1) 29- 35PubMedGoogle ScholarCrossref
Gottlieb  ABGriffiths  CEHo  VC  et al. Multi-Centre Investigator Group, Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.  Br J Dermatol 2005;152 (6) 1219- 1227PubMedGoogle ScholarCrossref
Wolff  KFleming  CHanifin  J  et al. Multicentre Investigator Group, Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.  Br J Dermatol 2005;152 (6) 1296- 1303PubMedGoogle ScholarCrossref
 US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051760.htmAccessed October 22 2009
 Pimecrolimus (marketed as Elidel cream). US Food and Drug Administration Web site.http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153524.htmAccessed October 22 2009
Margolis  DJHoffstad  OBilker  W Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.  Dermatology 2007;214 (4) 289- 295PubMedGoogle ScholarCrossref
Arellano  FMWentworth  CEArana  AFernandez  CPaul  CF Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.  J Invest Dermatol 2007;127 (4) 808- 816PubMedGoogle ScholarCrossref